Spotlight
Video

Dr. Debu Tripathy MD HER2+ early stage breast cancer outcomes have been significantly improved by the addition of trastuzumab to chemotherapy, with 1/3 to ½ fewer recurrences shown in large scale randomized trials.

videoblog has 63 videos Subscribe Here

Loading........
Description: HER2+ early stage breast cancer outcomes have been significantly improved by the addition of trastuzumab to chemotherapy, with 1/3 to ½ fewer recurrences shown in large scale randomized trials. However, anywhere from 0.4 to 3.8% of patients develop clinically significant cardiac toxicity, so calculating the projected absolute benefits balanced against the absolute risks of side effects is essential. Furthermore, both benefits and risks must be individualized. Age, history of hypertension and anthracycline exposure all increase the risk of cardiac toxicity. To refine individualized benefit estimates, prognostic factors might help stratify the relative and absolute benefit, but of the potential factors associated with trastuzumab resistance, such as PTEN loss, PI3K mutation, high IGF-1 receptor levels and others all need further validations before they are routinely used.
Shared By : videoblog
Posted on : 08/16/10
Added : 7 years ago
Category : Other



More From videoblog

Nothing found.